Hikma Pharmaceuticals launches caffeine citrate injection

Hikma Pharmaceuticals on Tuesday launched a caffeine citrate injection to treat apnea resulting from prematurity in infants of between 28 and 33 weeks of gestational age.The company noted that sales of caffeine citrate injections in the US last year were of $7.6m.Chairman and chief executive Said Darwazah said: "This is our first launch from the Bedford portfolio acquired last year."We are making good progress in the transfer of the Bedford products to our manufacturing facilities and this launch demonstrates our strong R&D, regulatory and manufacturing capabilities."Shares were down 2.58% to 2001p on Tuesday at 14:01. Hikma Pharmaceuticals